Funding Opportunity PAR-25-114 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports translational exploratory/developmental research that directly advances the discovery of novel treatment strategies, i.e., medical countermeasures (MCMs), that address serious morbidity and mortality after acute exposure to highly toxic chemical threats. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and ultra-potent synthetic (UPS) opioids. This NOFO supports translational research that includes, but is not limited to, preliminary efficacy and/or early preclinical development studies towards discovery and validation of novel molecular entities or biologics as candidate MCMs. In addition to novel agents, new treatment strategies may involve repurposing already FDA-approved products or combinations of interventions based on established mechanisms of action. Projects supported by this NOFO are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement program and/or other related initiatives.

Notice NOT-AA-24-013 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-077 from the NIH Guide for Grants and Contracts

Competitive: King's College London: About Us The post will be based in the research group of Professor Michael Simpson a multidisciplinary team with expertise in genetics, genomics, im London, United Kingdom

Competitive: Unreal Gigs: Are you passionate about using science to create breakthroughs in biotechnology that can revolutionize medicine, agriculture, and environmental sustai Cambridge, United Kingdom

Competitive: Unreal Gigs: Are you passionate about using science to create breakthroughs in biotechnology that can revolutionize medicine, agriculture, and environmental sustai London, United Kingdom

Competitive: Unreal Gigs: Are you passionate about turning complex biological data into meaningful insights that drive breakthroughs in health, medicine, and biotechnology? Do London, United Kingdom

Competitive: Unreal Gigs: Are you passionate about turning complex biological data into meaningful insights that drive breakthroughs in health, medicine, and biotechnology? Do Cambridge, United Kingdom

Notice NOT-DC-25-003 from the NIH Guide for Grants and Contracts

Notice NOT-PM-25-001 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-24-011 from the NIH Guide for Grants and Contracts. The Molecular Transducers of Physical Activity Consortium (MoTrPAC) has made data available through the MoTrPAC Data Hub (http://MoTrPAC-data.org). The purpose of this NOFO is to announce the availability of funding to support novel approaches for analyzing MoTrPAC data, to generate hypotheses and catalyze discoveries; for comparing the publicly released MoTrPAC data to other datasets; and for developing analytic pipelines.

Funding Opportunity RFA-MH-26-140 from the NIH Guide for Grants and Contracts. This NOFO solicits applications for next generation sensor and bioelectronic device development that will synchronize with brain recordings. The sensor and neural recording data will be used to generate new computational models of behavior in human and animal models. There has been a lack of quantitative approaches and models to understand the complexity of human and animal behavior in naturalistic settings. This NOFO focuses on the development of next generation sensors to acquire data and synchronize it with simultaneous brain recordings to build computational models.

Notice NOT-OD-25-017 from the NIH Guide for Grants and Contracts

Notice NOT-NS-25-004 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-24-009 from the NIH Guide for Grants and Contracts. The Common Fund Human Virome Program aims to extensively characterize the human virome and create tools, models, and methods that will enable an in-depth study of its variation in relation to host factors and its influence on health and disease. The purpose of this NOFO is to address the technological challenges that are currently hindering robust interrogation of the constituents and functionality of the human virome. Despite major advances in sequencing technology and computational analysis of large sequence data sets, challenges remain in examining viruses. This NOFO solicits applications to develop innovative and novel tools, models, and methods to overcome the major challenges in identifying and characterizing viruses, as well as the development of computational and bioinformatics tools to enhance the analysis of the human virome. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.

Funding Opportunity RFA-AI-24-069 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit applications to establish Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). These Centers will focus on developing preclinical assays, tools, and models for robust phage therapy research and development (R and D) and advancing phage clinical research.

Funding Opportunity PAR-25-057 from the NIH Guide for Grants and Contracts. To support UG3/UH3 phased, cooperative agreement research applications to plan and implement clinical trials within the mission of the National Institute of Dental and Craniofacial Research (NIDCR)

Competitive: Sygnature Discovery Limited: About the role As a growing drug discovery organisation, we are looking for highly motivated, enthusiastic, talented individuals keen to carry out th Nottingham, United Kingdom

Funding Opportunity PA-25-212 from the NIH Guide for Grants and Contracts. Through this I-Corps at NIH program Notice of Funding Opportunity (NOFO), NIH and CDC provide administrative supplement awards to active SBIR (NIH and CDC) and STTR Phase I (NIH only) grantees/awardees. The I-Corps at NIH mission is to empower entrepreneurs in developing and validating a strategic business model through diverse customer discovery in order to meet unmet clinical needs. I-Corps enables and accelerates the transformation of invention to impact SBIR and STTR Phase I awardees in a no-cost extension are eligible as long as, if selected, their no cost extension covers the entire duration of I-Corps at NIH cohort. The program provides three-member project teams with access to instruction and mentoring to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact Scientific/Research staff for more information about the program before applying.

Funding Opportunity PAR-25-059 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.